Nasdaq.com's news article titled: "Hologic Inc Earnings Decline 2% In Q4" with publication date: November 08, 2017 was also an interesting one.
A number of institutional investors have recently modified their holdings of HOLX. BTIG Research reissued a buy rating and set a $44.00 target price on shares of Hologic in a research report on Thursday, July 28th.
October 2 investment analysts at Needham & Company LLC held the stock rating at "Buy" targeting a price of $50.00. Zacks Investment Research lowered Hologic from a "hold" rating to a "sell" rating in a research report on Tuesday, October 17th.
October 10 investment analysts at Jefferies Group LLC held the company rating at "Buy" projecting a price of $44.00. Stifel Nicolaus upgraded the shares of HOLX in report on Friday, December 11 to "Buy" rating.
COPYRIGHT VIOLATION NOTICE: "Gabelli Weighs in on Hologic, Inc.'s FY2018 Earnings (HOLX)" was first published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of USA and global copyright laws. RBC Capital Markets reissued a sector perform rating and set a $39.00 target price (up from $37.00) on shares of Hologic in a research report on Monday, August 1st.
The company is so far trading down by 2.41% since yesterday's close of 40.64. The stock has a market capitalization of $10.32 billion, a PE ratio of 41.00 and a beta of 1.13. Hologic has a one year low of $35.76 and a one year high of $46.80. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78. (NASDAQ:HOLX) advice adding it to buy candidate list. During the same quarter last year, the company posted $0.52 EPS. equities analysts predict that Hologic will post 2.12 earnings per share for the current year. The firm had revenue of $802.90 million during the quarter, compared to analysts' expectations of $792.54 million. The firm's revenue for the quarter was up 10.5% compared to the same quarter a year ago. During the same period in the prior year, the firm posted $0.52 EPS.
In related news, VP Karleen Marie Oberton sold 1,256 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $39.88, for a total transaction of $727,251.68. Following the completion of the sale, the vice president now directly owns 9,406 shares of the company's stock, valued at approximately $369,561.74. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Elaine Ullian sold 18,236 shares of the business's stock in a transaction that occurred on Monday, October 10th. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,667 shares of company stock worth $969,299. Corporate insiders own 0.84% of the company's stock. (NASDAQ:HOLX). Eastern National Bank & Trust has invested 0.65% in Hologic, Inc. Dimensional Fund Advisors Lp augmented its ownership by buying 105,360 shares an increase of 5.7% in the quarter. Of those holders, 240 had increased positions amounting to 42.37 million shares, 253 had decreased positions amounting to 41.71 million shares, and 63 holders have a held position accounting for 186.05 million shares. The sales growth over the last 5 years is at 8.80% while earning per share for the last 12 months is at 2.64. AQR Capital Management LLC increased its position in shares of Hologic by 56.1% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider's stock worth $114,000 after buying an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC bought a new stake in Hologic in the second quarter valued at about $191,000.
Connor Clark & Lunn Investment Management Ltd, which manages about $26.75 billion and $15.22B US Long portfolio, decreased its stake in Ptc Therapeutics Inc (NASDAQ:PTCT) by 36,750 shares to 36,075 shares, valued at $661,000 in 2017Q2, according to the filing. Institutional investors and hedge funds own 96.41% of the company's stock.